| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
151: A case for change: Palliative home oxygen in a tertiary cancer centre
|
Modarres, P.
|
|
2017
|
103 |
S1 |
p. S68-S69
2 p.
|
artikel
|
| 2 |
11: A case study of dual pathology of lung cancer
|
Rashid, M.
|
|
2017
|
103 |
S1 |
p. S6-
1 p.
|
artikel
|
| 3 |
118: Accelerated hypofractionated intensity modulated radiotherapy (IMRT) for early stage non-small cell lung cancer (NSCLC) in patients not suitable for conventional stereotactic ablative radiotherapy (SABR)
|
Lavin, V.
|
|
2017
|
103 |
S1 |
p. S53-S54
2 p.
|
artikel
|
| 4 |
57: Access to mesothelioma services in Yorkshire. An audit of patients diagnosed with malignant mesothelioma in West & North Yorkshire during 2015
|
Bolton, S.P.
|
|
2017
|
103 |
S1 |
p. S26-
1 p.
|
artikel
|
| 5 |
33: Adequacy of image-guided rebiopsies for molecular retesting in advanced NSCLC: a single centre experience
|
Tokaca, N.
|
|
2017
|
103 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 6 |
70: Adjuvant chemotherapy for NSCLC: Experience from one cancer centre
|
Smith, T.
|
|
2017
|
103 |
S1 |
p. S33-S34
2 p.
|
artikel
|
| 7 |
171: ADSCaN: A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer (NSCLC)
|
Lawless, C.A.
|
|
2017
|
103 |
S1 |
p. S80-S81
2 p.
|
artikel
|
| 8 |
23: Advanced lung cancer in East Lancashire. What can improve inpatient mortality?
|
Nwosu, N.
|
|
2017
|
103 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 9 |
78: A local service evaluation to assess the management of patients with advanced non-small-cell lung cancer on nivolumab
|
Ramessur, A.
|
|
2017
|
103 |
S1 |
p. S37-
1 p.
|
artikel
|
| 10 |
10: A lung nodule unveiling a rare primary pulmonary leiomyosarcoma
|
Terrington, D.
|
|
2017
|
103 |
S1 |
p. S5-
1 p.
|
artikel
|
| 11 |
42: An audit of the frequency of immunochemical expression of CDX2 within lung carcinomas
|
Shah, B.
|
|
2017
|
103 |
S1 |
p. S19-
1 p.
|
artikel
|
| 12 |
96: An evaluation of a lung cancer research training for nurses: Thoracic Oncology Research from Concept to Home Run (TORCH)
|
Tod, A.M.
|
|
2017
|
103 |
S1 |
p. S44-
1 p.
|
artikel
|
| 13 |
31: A new NHS diagnostic service to detect EGFR ctDNA mutations in non-small cell lung cancer patients
|
Williams, A.S.
|
|
2017
|
103 |
S1 |
p. S14-
1 p.
|
artikel
|
| 14 |
38: An overview of endobronchial ultrasound practice in the Belfast Trust – how are we doing?
|
Moore, I.
|
|
2017
|
103 |
S1 |
p. S18-
1 p.
|
artikel
|
| 15 |
167: A phase I/II trial of combination nab-paclitaxel and nintedanib or nab-paclitaxel and placebo in relapsed NSCLC adenocarcinoma (N3)
|
Tokaca, N.
|
|
2017
|
103 |
S1 |
p. S77-S78
2 p.
|
artikel
|
| 16 |
8: Are circRNAs potentially useful for the early detection of lung cancer?
|
Lin, R.C.
|
|
2017
|
103 |
S1 |
p. S4-S5
2 p.
|
artikel
|
| 17 |
36: A retrospective audit of the complication and success rates of CT-guided lung biopsies performed within Leicester Glenfield Hospital
|
Tyagi, N.
|
|
2017
|
103 |
S1 |
p. S17-
1 p.
|
artikel
|
| 18 |
62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England
|
Yip, K.
|
|
2017
|
103 |
S1 |
p. S28-S29
2 p.
|
artikel
|
| 19 |
53: A survey of regional practice affecting small sample diagnosis and tissue managment of lung carcinoma samples, with development of a local guideline
|
Basnet, M.
|
|
2017
|
103 |
S1 |
p. S24-S25
2 p.
|
artikel
|
| 20 |
40: A UK multi-centre survey of endobronchial and transbronchial biopsy experience in respiratory specialist trainees and consultants
|
Fallon, J.E.
|
|
2017
|
103 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 21 |
Author Index
|
|
|
2017
|
103 |
S1 |
p. S82-S86
5 p.
|
artikel
|
| 22 |
126: Automated classification of radiation oesophagitis from free text clinical narratives
|
Dehghan, A.
|
|
2017
|
103 |
S1 |
p. S57-S58
2 p.
|
artikel
|
| 23 |
97: Barriers to early detection of lung cancer in Ireland
|
McNamara, A.
|
|
2017
|
103 |
S1 |
p. S44-S45
2 p.
|
artikel
|
| 24 |
131: Can a Consultant Radiographer prescribe palliative radiotherapy safely and improve service?
|
Moore, K.
|
|
2017
|
103 |
S1 |
p. S59-S60
2 p.
|
artikel
|
| 25 |
91: Can the early intervention of the Lung Cancer CNS reduce the length of stay for patients admitted via the emergency route on first presentation?
|
Shepherd, P.
|
|
2017
|
103 |
S1 |
p. S43-
1 p.
|
artikel
|
| 26 |
68: Carboplatin monotherapy in patients with stage 4 NSCLC
|
Rodgers, L.
|
|
2017
|
103 |
S1 |
p. S31-S32
2 p.
|
artikel
|
| 27 |
64: Characteristics and treatment of NSCLC patients with ALK translocation, a single centre experience
|
Postmus, P.E.
|
|
2017
|
103 |
S1 |
p. S30-
1 p.
|
artikel
|
| 28 |
109: Characteristics of HIV-associated lung cancer
|
Samani, A.
|
|
2017
|
103 |
S1 |
p. S49-
1 p.
|
artikel
|
| 29 |
81: Circulating tumour DNA testing in advanced EGFR positive NSCLC; a DGH experience of validation and clinical application of serum testing
|
Jarvis, R.S.
|
|
2017
|
103 |
S1 |
p. S38-
1 p.
|
artikel
|
| 30 |
123: Concurrent chemoradiation for NSCLC: improving outcomes with modern techniques
|
Kuciejewska, A.
|
|
2017
|
103 |
S1 |
p. S56-
1 p.
|
artikel
|
| 31 |
142: CONVERT – An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS)
|
Faivre-Finn, C.
|
|
2017
|
103 |
S1 |
p. S64-
1 p.
|
artikel
|
| 32 |
122: CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases
|
Khoo, V.
|
|
2017
|
103 |
S1 |
p. S55-S56
2 p.
|
artikel
|
| 33 |
147: Cost effectiveness of a tunneled indwelling pleural catheter service for malignant pleural effusions secondary to lung cancer and mesothelioma
|
Madani, Y.
|
|
2017
|
103 |
S1 |
p. S66-S67
2 p.
|
artikel
|
| 34 |
63: Crizotinib for ALK rearrangement in non small cell lung cancer
|
Merrick, S.A.
|
|
2017
|
103 |
S1 |
p. S29-S30
2 p.
|
artikel
|
| 35 |
39: CT-PET and EBUS – Results of a network wide audit of EBUS use
|
Lawson, M.
|
|
2017
|
103 |
S1 |
p. S18-
1 p.
|
artikel
|
| 36 |
128: 90-day mortality after radical radiotherapy and 30-day mortality after high dose palliative radiotherapy in lung cancer patients at the University Hospitals Birmingham
|
Maung Maung Myint, Y.
|
|
2017
|
103 |
S1 |
p. S58-
1 p.
|
artikel
|
| 37 |
158: Defining molecular residual disease after lung cancer resection
|
Leung, M.
|
|
2017
|
103 |
S1 |
p. S72-S73
2 p.
|
artikel
|
| 38 |
155: Detecting early asymptomatic recurrence in resected lung cancer – When is the optimal time for initial imaging?
|
Roberts, S.
|
|
2017
|
103 |
S1 |
p. S71-
1 p.
|
artikel
|
| 39 |
90: Developing a lung cancer nurse led telephone review clinic
|
Howison, H.S.
|
|
2017
|
103 |
S1 |
p. S42-
1 p.
|
artikel
|
| 40 |
102: Developing a recovery based approach to cancer care in NHS Lothian
|
Knowles, G.
|
|
2017
|
103 |
S1 |
p. S46-
1 p.
|
artikel
|
| 41 |
161: Development of a specialist patient website for thoracic surgery
|
Oswald, N.
|
|
2017
|
103 |
S1 |
p. S74-
1 p.
|
artikel
|
| 42 |
6: Development of non-invasive imaging of integrin alpha-v-beta-6 (αvβ6)-positive lung cancers in advance of testing αvβ6-targeted therapies
|
Rudran, B.
|
|
2017
|
103 |
S1 |
p. S4-
1 p.
|
artikel
|
| 43 |
45: Diagnostic pathway in suspected lung cancer according to ACCP radiographic groups on CT chest
|
Edwards, T.
|
|
2017
|
103 |
S1 |
p. S20-S21
2 p.
|
artikel
|
| 44 |
41: Diagnostic performance of PET-CT for anterior mediastinal lesions – the DECiMaL study
|
Proli, C.
|
|
2017
|
103 |
S1 |
p. S19-
1 p.
|
artikel
|
| 45 |
77: Does age impact on treatment? An audit of treatment and outcomes for patients with metastatic non-small cell lung cancer
|
Hockings, H.A.
|
|
2017
|
103 |
S1 |
p. S36-S37
2 p.
|
artikel
|
| 46 |
50: Does interval NSCLC tumour growth between referral and treatment result in significant upstaging when using the revised 8th TNM classification?
|
Govindrai, R.
|
|
2017
|
103 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 47 |
121: Dosimetric implications for radical radiation therapy on the 1.5 Tesla Magnetic Resonance Linear Accelerator (MR-Linac) in locally-advanced non-small cell lung cancer
|
Bainbridge, H.
|
|
2017
|
103 |
S1 |
p. S55-
1 p.
|
artikel
|
| 48 |
76: Double whammy or double bonanza? Report of compound/double EGFR mutation in NSCLC patients from a cancer centre in Eastern India
|
Shrimali, R.
|
|
2017
|
103 |
S1 |
p. S36-
1 p.
|
artikel
|
| 49 |
110: Drug interactions with systemic anti-cancer therapy in lung cancer patients
|
Panchal, R.
|
|
2017
|
103 |
S1 |
p. S49-S50
2 p.
|
artikel
|
| 50 |
71: Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA)
|
Lewis, P.J.
|
|
2017
|
103 |
S1 |
p. S34-
1 p.
|
artikel
|
| 51 |
Editorial Board
|
|
|
2017
|
103 |
S1 |
p. i-
1 p.
|
artikel
|
| 52 |
37: Efficacy and safety of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) in patients with poor lung function and/or WHO performance status
|
Malhotra, P.
|
|
2017
|
103 |
S1 |
p. S17-S18
2 p.
|
artikel
|
| 53 |
25: Efficacy of a fast track lung cancer email referral system
|
Sapru, K.
|
|
2017
|
103 |
S1 |
p. S11-
1 p.
|
artikel
|
| 54 |
9: EGFR-AS1: A potential biomarker for sensitivity to EGFR TKIs in NSCLC?
|
Heery, R.
|
|
2017
|
103 |
S1 |
p. S5-
1 p.
|
artikel
|
| 55 |
75: EGFR-mutant non-small cell lung cancer in Aberdeen, Scotland – Treatment and outcomes
|
El-Shakankery, K.
|
|
2017
|
103 |
S1 |
p. S35-S36
2 p.
|
artikel
|
| 56 |
22: Emergency presentation of lung cancer patients in a university hospital
|
Kene, S.
|
|
2017
|
103 |
S1 |
p. S10-
1 p.
|
artikel
|
| 57 |
15: Endoscopic management of an endobronchial lipoma – A rare tumour
|
Miller, R.
|
|
2017
|
103 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 58 |
13: Epidermal growth factor receptor (EGFR) mutated advanced squamous cell lung cancer – treatment beyond progression
|
O'Leary, C.G.
|
|
2017
|
103 |
S1 |
p. S6-
1 p.
|
artikel
|
| 59 |
48: Evaluating the use of PET-CT scan requests in the lung cancer diagnostic pathway – are we overusing this valuable resource?
|
Crawford, E.
|
|
2017
|
103 |
S1 |
p. S22-
1 p.
|
artikel
|
| 60 |
150: Experience of Carina/Y-stent use in management of central airway obstruction
|
Brown, R.
|
|
2017
|
103 |
S1 |
p. S68-
1 p.
|
artikel
|
| 61 |
58: Experience of palliative chemotherapy for malignant meosthelioma in a DGH setting
|
Patterson, D.M.
|
|
2017
|
103 |
S1 |
p. S26-S27
2 p.
|
artikel
|
| 62 |
153: Experiences of setting up a pre-operative optimisation ‘pre-hab’ service for patients being considered for lung cancer surgery
|
Bollard, K.
|
|
2017
|
103 |
S1 |
p. S69-
1 p.
|
artikel
|
| 63 |
47: Exposure of patients to ionising radiation during lung cancer diagnostic work-up
|
Atherton, R.
|
|
2017
|
103 |
S1 |
p. S21-
1 p.
|
artikel
|
| 64 |
127: 18-F fluorodeoxygenase (FDG) positron emission tomography (PET) scanning prior to radical lung radiotherapy. A retrospective audit of practice
|
Bainbridge, H.
|
|
2017
|
103 |
S1 |
p. S58-
1 p.
|
artikel
|
| 65 |
3: Germline sequencing of DIPNECH patients reveals a heterogeneous disease with novel SNVs in genes that are somatically mutated in other neuroendocrine malignancies
|
Hudson, A.M.
|
|
2017
|
103 |
S1 |
p. S2-
1 p.
|
artikel
|
| 66 |
104: Group pre-assessment for patients undergoing chemotherapy: Our experience at The Royal Shrewsbury Hospital
|
Allos, B.
|
|
2017
|
103 |
S1 |
p. S47-
1 p.
|
artikel
|
| 67 |
100: Guideline for smoking cessation prior to lung cancer treatment
|
Dixon, S.
|
|
2017
|
103 |
S1 |
p. S45-S46
2 p.
|
artikel
|
| 68 |
125: HALT: Targeted therapy beyond progression with or without dose-intensified radiotherapy in oligoprogressive disease in oncogene addicted lung tumours
|
McDonald, F.
|
|
2017
|
103 |
S1 |
p. S57-
1 p.
|
artikel
|
| 69 |
98: Healthcare professionals' perspectives on transferring patients to theatre at a tertiary centre for thoracic cancer surgery – The Walk or Wheeled (WoW) Project
|
De Sousa, P.
|
|
2017
|
103 |
S1 |
p. S45-
1 p.
|
artikel
|
| 70 |
34: High diagnostic accuracy in lung cancer biopsy samples outside cancer centres can be achieved with sub-speciality interest
|
Viola, P.
|
|
2017
|
103 |
S1 |
p. S16-
1 p.
|
artikel
|
| 71 |
4: High resolution toxicity analysis of lung cancer patients identifies the base of the heart as a dose sensitive region
|
McWilliam, A.
|
|
2017
|
103 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 72 |
93: Holistic needs assessment – development of the virtual clinic
|
Smith, R.
|
|
2017
|
103 |
S1 |
p. S43-
1 p.
|
artikel
|
| 73 |
140: Hospital admissions for febrile neutropenia in patients with small-cell lung cancer receiving carboplatin and etoposide chemotherapy
|
Tay, J.
|
|
2017
|
103 |
S1 |
p. S63-S64
2 p.
|
artikel
|
| 74 |
111: How good is lung cancer education in primary care and how can the Christie Lung Cancer Group improve this?
|
Coote, J.
|
|
2017
|
103 |
S1 |
p. S50-
1 p.
|
artikel
|
| 75 |
18: How has including “unexplained haemoptysis” in 2015 NICE lung cancer referral guidelines changed referral and diagnosis rates?
|
Dobson, S.
|
|
2017
|
103 |
S1 |
p. S9-
1 p.
|
artikel
|
| 76 |
54: How reliable is the chest X-ray to diagnose lung cancer in symptomatic patients? An audit of a single South London NHS Trust
|
Walder, D.P.
|
|
2017
|
103 |
S1 |
p. S25-
1 p.
|
artikel
|
| 77 |
84: How useful is the chest x-ray after 1 cycle of palliative chemotherapy?
|
Pearlman, E.
|
|
2017
|
103 |
S1 |
p. S39-
1 p.
|
artikel
|
| 78 |
94: Identifying the differing holistic needs of the population of lung cancer patients aged 55 and under
|
Watts, J.
|
|
2017
|
103 |
S1 |
p. S44-
1 p.
|
artikel
|
| 79 |
120: Impact of introducing intensity modulated radiotherapy (IMRT) on curative-intent radiotherapy for lung cancer – a ‘big data’ analysis
|
Chan, C.
|
|
2017
|
103 |
S1 |
p. S54-S55
2 p.
|
artikel
|
| 80 |
95: Improving prehabilitation information and advice for lung cancer/mesothelioma patients
|
Clayton, K.J.
|
|
2017
|
103 |
S1 |
p. S44-
1 p.
|
artikel
|
| 81 |
83: Improving the Cancer Research UK Stratified Medicine Programme 2 (CRUK-SMP2) pathway: an audit in Cardiff and Vale University Health Board (CAVUHB)
|
Rhys, G.H.
|
|
2017
|
103 |
S1 |
p. S39-
1 p.
|
artikel
|
| 82 |
103: Independent prescribing pharmacist clinics; how they can benefit oncology services
|
Bendle, M.
|
|
2017
|
103 |
S1 |
p. S46-S47
2 p.
|
artikel
|
| 83 |
101: Information Days – supporting patients and carers
|
Forrest, N.
|
|
2017
|
103 |
S1 |
p. S46-
1 p.
|
artikel
|
| 84 |
19: Intra-operative frozen sections – is video-link technology equivalent to an on-site service?
|
French, J.
|
|
2017
|
103 |
S1 |
p. S9-
1 p.
|
artikel
|
| 85 |
137: Is there still a role for continuous hyperfractionated accelerated radiotherapy (CHART) in the management of NSCLC?
|
Price, J.
|
|
2017
|
103 |
S1 |
p. S61-S62
2 p.
|
artikel
|
| 86 |
24: Leeds Survivorship Program; CT follow-up after radical surgery
|
Ellames, D.A.B.
|
|
2017
|
103 |
S1 |
p. S11-
1 p.
|
artikel
|
| 87 |
156: Left upper lobe lung resection in patients with left internal mammary artery (LIMA) coronary bypass graft, a case series
|
Singh, S.S. Avtaar
|
|
2017
|
103 |
S1 |
p. S71-S72
2 p.
|
artikel
|
| 88 |
169: Lung ART: Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement
|
Faivre-Finn, C.
|
|
2017
|
103 |
S1 |
p. S79-
1 p.
|
artikel
|
| 89 |
61: Lung sparing surgery for mesothelioma is a safe and effective modality in the treatment of malignant mesothelioma
|
Hussain, A.
|
|
2017
|
103 |
S1 |
p. S28-
1 p.
|
artikel
|
| 90 |
163: LungTech Stereotactic Body Radiotherapy (SBRT) of inoperable centrally located NSCLC: A phase II study in preparation for a randomised phase III trial
|
Faivre-Finn, C.
|
|
2017
|
103 |
S1 |
p. S74-S75
2 p.
|
artikel
|
| 91 |
16: Lymphoma presenting as sub-acute central airway obstruction (CAO)
|
Khan, S. Leyakathali
|
|
2017
|
103 |
S1 |
p. S8-
1 p.
|
artikel
|
| 92 |
65: Maintenance pemetrexed for non-squamous non-small cell lung cancer (NSCLC): ‘real life’ outcomes from a UK centre
|
Lim, J.
|
|
2017
|
103 |
S1 |
p. S30-S31
2 p.
|
artikel
|
| 93 |
114: Management and outcomes of large cell neuroendocrine lung cancer
|
McAvan, L.
|
|
2017
|
103 |
S1 |
p. S51-S52
2 p.
|
artikel
|
| 94 |
27: Management and outcomes of patients with non-small cell lung cancer (NSCLC) and synchronous brain metastases: A multicentre retrospective review
|
Cook, M.
|
|
2017
|
103 |
S1 |
p. S12-
1 p.
|
artikel
|
| 95 |
138: Management of stage 3 non-small cell lung cancer with radical radiotherapy in a CHART centre
|
Pascoe, A.
|
|
2017
|
103 |
S1 |
p. S62-
1 p.
|
artikel
|
| 96 |
134: Marked variability in the access to curative radiotherapy for NSCLC in the UK
|
McAleese, J.
|
|
2017
|
103 |
S1 |
p. S60-S61
2 p.
|
artikel
|
| 97 |
108: Mesothelioma and lung cancer patient support group – a 2 year review
|
Williams, S.M.
|
|
2017
|
103 |
S1 |
p. S48-S49
2 p.
|
artikel
|
| 98 |
112: Microwave ablation of malignant lung lesions – the King's experience
|
Tran, S.
|
|
2017
|
103 |
S1 |
p. S50-
1 p.
|
artikel
|
| 99 |
56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma
|
Baird, A.
|
|
2017
|
103 |
S1 |
p. S26-
1 p.
|
artikel
|
| 100 |
82: Mutational testing in lung adenocarcinoma patients – Are we testing everyone we should be?
|
Jones, R.
|
|
2017
|
103 |
S1 |
p. S38-S39
2 p.
|
artikel
|
| 101 |
105: National Thoracic surgery PPI group identify key questions in routine clinical care for further research
|
Kadiri, S.
|
|
2017
|
103 |
S1 |
p. S47-S48
2 p.
|
artikel
|
| 102 |
43: Non small cell lung cancer mutational testing in the South East of Ireland
|
O'Leary, C.G.
|
|
2017
|
103 |
S1 |
p. S20-
1 p.
|
artikel
|
| 103 |
7: Normal bronchial epithelial cells exhibit altered cellular behaviour when exposed to lung cancer cells in a co-culture system
|
Baird, A.
|
|
2017
|
103 |
S1 |
p. S4-
1 p.
|
artikel
|
| 104 |
99: Nurse led helpline and online support service
|
Forrest, N.
|
|
2017
|
103 |
S1 |
p. S45-
1 p.
|
artikel
|
| 105 |
89: Optimising the patient pathway with early CNS intervention
|
Dunbar, J.L.
|
|
2017
|
103 |
S1 |
p. S42-
1 p.
|
artikel
|
| 106 |
117: Organ at risk inter- and intra-observer contour variation for lung patients on average versus motion compensated 4DCT
|
McWilliam, A.
|
|
2017
|
103 |
S1 |
p. S52-S53
2 p.
|
artikel
|
| 107 |
160: Outcome of surgically resected primary pulmonary carcinoid tumors
|
Rajnish, R.K.
|
|
2017
|
103 |
S1 |
p. S73-S74
2 p.
|
artikel
|
| 108 |
124: Outcomes following concurrent chemoradiotherapy for stage II and III non small cell lung cancer (NSCLC) at Leeds Cancer Centre (LCC) in 2014
|
Sun, F.
|
|
2017
|
103 |
S1 |
p. S56-S57
2 p.
|
artikel
|
| 109 |
113: Outcomes of malignant pulmonary nodule: a tertiary centre review
|
Ali, A.
|
|
2017
|
103 |
S1 |
p. S50-S51
2 p.
|
artikel
|
| 110 |
67: Outcomes of patients in South Yorkshire who received maintenance pemetrexed treatment for non-squamous, non-small-cell cancer after induction chemotherapy with pemetrexed and cisplatin
|
Kakoudaki, M.
|
|
2017
|
103 |
S1 |
p. S31-
1 p.
|
artikel
|
| 111 |
66: Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum non-pemetrexed doublet chemotherapy
|
Marshall, R.
|
|
2017
|
103 |
S1 |
p. S31-
1 p.
|
artikel
|
| 112 |
69: Outcomes with nintedanib and docetaxel in patients with relapsed NSCLC adenocarcinoma treated within the UK Nintedanib Individual Patient Supply programme
|
Tokaca, N.
|
|
2017
|
103 |
S1 |
p. S32-S33
2 p.
|
artikel
|
| 113 |
59: Palliative radiotherapy for malignant pleural mesothelioma – The Christie experience
|
Blaum, C.
|
|
2017
|
103 |
S1 |
p. S27-
1 p.
|
artikel
|
| 114 |
133: Palliative whole brain radiotherapy in metastatic lung cancer
|
Coventry, T.P.
|
|
2017
|
103 |
S1 |
p. S60-
1 p.
|
artikel
|
| 115 |
164: PARIS: A phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC)
|
Kordbacheh, T.
|
|
2017
|
103 |
S1 |
p. S75-S76
2 p.
|
artikel
|
| 116 |
106: Patient experiences and factors affecting adherence to pulmonary rehabilitation classes before and after lung surgery – the need for a tailored programme
|
Kadiri, S.
|
|
2017
|
103 |
S1 |
p. S48-
1 p.
|
artikel
|
| 117 |
20: Pattern of lung cancer referrals to a newly established Acute Oncology Service
|
Mulholland, L.E.
|
|
2017
|
103 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 118 |
168: PD-RAD: A translational study investigating PD-L1 expression after radiotherapy for non-small cell lung cancer (NSCLC)
|
Kordbacheh, T.
|
|
2017
|
103 |
S1 |
p. S78-S79
2 p.
|
artikel
|
| 119 |
165: PePS2: Pembrolizumab in Performance Status 2 non-small-cell lung cancer
|
Brock, K.
|
|
2017
|
103 |
S1 |
p. S76-
1 p.
|
artikel
|
| 120 |
170: Photodynamic therapy for the prevention of lung cancer (The PEARL trial)
|
Thakrar, R.M.
|
|
2017
|
103 |
S1 |
p. S79-S80
2 p.
|
artikel
|
| 121 |
148: Pleural effusion management in a District General Hospital (DGH): Respiratory Registrar experience
|
Khalid, T.
|
|
2017
|
103 |
S1 |
p. S67-
1 p.
|
artikel
|
| 122 |
12: Pleural mesothelioma: The painful reality
|
Higgins, L.S.
|
|
2017
|
103 |
S1 |
p. S6-
1 p.
|
artikel
|
| 123 |
107: Positive impact on patient's journey through involvement in thoracic surgery clinical trials
|
Kerr, A.
|
|
2017
|
103 |
S1 |
p. S48-
1 p.
|
artikel
|
| 124 |
28: Preliminary ‘virtual review’ of lung cancer MDT cases: The impact on diagnostic pathways and MDT meeting efficiency
|
Bull, A.
|
|
2017
|
103 |
S1 |
p. S13-
1 p.
|
artikel
|
| 125 |
157: Pulmonary nodules with mild and moderate fluorodeoxyglucose (FDG) uptake – a three year review
|
Akhtar, S.
|
|
2017
|
103 |
S1 |
p. S72-
1 p.
|
artikel
|
| 126 |
139: Radical re-irradiation for localised recurrence in lung cancer patients – A single centre experience
|
Abdullah, S.
|
|
2017
|
103 |
S1 |
p. S62-S63
2 p.
|
artikel
|
| 127 |
144: Radiotherapy practice in patients with extensive stage small-cell lung cancer responding to platinum chemotherapy at The Royal Marsden Hospital
|
Dunne, E.M.
|
|
2017
|
103 |
S1 |
p. S65-
1 p.
|
artikel
|
| 128 |
88: Rate of neutropenic sepsis in relapsed NSCLC patients receiving docetaxel chemotherapy
|
Gyi, M.M.
|
|
2017
|
103 |
S1 |
p. S41-S42
2 p.
|
artikel
|
| 129 |
79: Real-world use of checkpoint inhibitors in the management of thoracic malignancies: a single-institution experience
|
Lynch, J.
|
|
2017
|
103 |
S1 |
p. S37-
1 p.
|
artikel
|
| 130 |
162: Receiving a diagnosis of mesothelioma: Improving the patient experience
|
Tod, A.M.
|
|
2017
|
103 |
S1 |
p. S74-
1 p.
|
artikel
|
| 131 |
136: Reducing time to radical radiotherapy for lung cancer in Greater Manchester and East Cheshire
|
Bayman, N.
|
|
2017
|
103 |
S1 |
p. S61-
1 p.
|
artikel
|
| 132 |
92: Re-evaluation of the support worker within the lung cancer team
|
Guerin, M.
|
|
2017
|
103 |
S1 |
p. S43-
1 p.
|
artikel
|
| 133 |
135: Re-plan rates for radical radiotherapy in lung cancer
|
Walls, G.M.
|
|
2017
|
103 |
S1 |
p. S61-
1 p.
|
artikel
|
| 134 |
87: Resource use associated with the management of docetaxel-related haematological toxicities, including neutropenic sepsis (NS), in patients with advanced non-small cell lung cancer (NSCLC) in the UK NHS: REVEAL-NS
|
Talbot, T.
|
|
2017
|
103 |
S1 |
p. S41-
1 p.
|
artikel
|
| 135 |
132: Role and outcomes of high dose palliative thoracic radiotherapy at the Beatson West of Scotland Cancer Centre
|
Campbell, K.
|
|
2017
|
103 |
S1 |
p. S60-
1 p.
|
artikel
|
| 136 |
130: Routine implementation of electronic patient reported outcomes (ePRO) in lung cancer patients
|
Ala'Aldeen, K.
|
|
2017
|
103 |
S1 |
p. S59-
1 p.
|
artikel
|
| 137 |
119: SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer (NSCLC). A UK randomised phase III trial
|
Landau, D.B.
|
|
2017
|
103 |
S1 |
p. S54-
1 p.
|
artikel
|
| 138 |
32: Screening for brain metastases in non small cell lung cancer (NSCLC)
|
Harris, M.
|
|
2017
|
103 |
S1 |
p. S14-
1 p.
|
artikel
|
| 139 |
166: Searching for MARS-2: The North Trent Cancer Research Network Specialist Mesothelioma MDT screening experience
|
Ajab, S.
|
|
2017
|
103 |
S1 |
p. S76-S77
2 p.
|
artikel
|
| 140 |
85: Single MDT 30-day mortality after systemic anticancer therapy (SACT) for lung cancer in an NHS trust serving an English and Welsh population
|
Decatris, M.P.
|
|
2017
|
103 |
S1 |
p. S40-
1 p.
|
artikel
|
| 141 |
141: Small cell lung cancer: Is there a role for chemotherapy in patients with poor performance status?
|
Massalha, S.
|
|
2017
|
103 |
S1 |
p. S64-
1 p.
|
artikel
|
| 142 |
116: Somatic and germline mutations in thymic epithelial tumours and their correlation with histological and clinical phenotypes
|
Gennatas, S.
|
|
2017
|
103 |
S1 |
p. S52-
1 p.
|
artikel
|
| 143 |
55: Somatic BAP1 and NF2 mutations in pleural malignant mesothelioma and their correlation with clinical phenotype
|
Gennatas, S.
|
|
2017
|
103 |
S1 |
p. S25-S26
2 p.
|
artikel
|
| 144 |
26: Stereotactic body radiotherapy for primary lung cancer: Referral to treatment pathway experiences from a tertiary referral centre
|
Hunt, A.K.
|
|
2017
|
103 |
S1 |
p. S11-S12
2 p.
|
artikel
|
| 145 |
14: Superior vena cava obstruction (SVCO) syndrome caused by a ball like endovascular metastatic small cell lung cancer mass: A case report
|
Osman, W.
|
|
2017
|
103 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 146 |
129: Survival for patients following radical radiotherapy in the Northern Ireland cancer network in comparison to a large European cohort
|
McAleese, J.
|
|
2017
|
103 |
S1 |
p. S58-S59
2 p.
|
artikel
|
| 147 |
60: SYSTEMS-2: Generation of dose constraints for a hypofractionated, dose escalated radiotherapy regimen for malignant pleural mesothelioma
|
Ashton, M.
|
|
2017
|
103 |
S1 |
p. S27-S28
2 p.
|
artikel
|
| 148 |
80: Testing for programmed death receptor ligand (PD-L1) in metastatic non-small-cell lung cancer (NSCLC) patients; the Heart of England NHS Foundation Trust (HEFT) experience
|
Bancroft, H.
|
|
2017
|
103 |
S1 |
p. S37-S38
2 p.
|
artikel
|
| 149 |
30: Testing of EGFR mutations and ALK translocations in patients diagnosed with adenocarcinoma at Great Western Hospital, Swindon
|
Jones, H.
|
|
2017
|
103 |
S1 |
p. S13-S14
2 p.
|
artikel
|
| 150 |
21: The acute presentation of lung cancer – How well are we performing?
|
Hufton, A.
|
|
2017
|
103 |
S1 |
p. S10-
1 p.
|
artikel
|
| 151 |
115: The effect of EGFR sensitising mutation on survival in advanced lung cancer – a ‘real-world’ analysis
|
Kennedy, M.P.T.
|
|
2017
|
103 |
S1 |
p. S52-
1 p.
|
artikel
|
| 152 |
49: The effects of a lung cancer triage service on the ‘62-day target’
|
Balata, H.
|
|
2017
|
103 |
S1 |
p. S22-
1 p.
|
artikel
|
| 153 |
52: The incidence and association of thrombocytosis in people referred to the suspected lung cancer clinic
|
Jones, G.
|
|
2017
|
103 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 154 |
143: The management of patients with extensive-stage small-cell lung cancer: A European survey of practice
|
Haslett, K.
|
|
2017
|
103 |
S1 |
p. S64-S65
2 p.
|
artikel
|
| 155 |
29: The NHS Wales–Novartis joint working project on lung cancer
|
Lester, J.F.
|
|
2017
|
103 |
S1 |
p. S13-
1 p.
|
artikel
|
| 156 |
86: The rate of neutropenic sepsis (NS) and other haematological toxicities in patients with advanced non-small cell lung cancer (NSCLC) treated with docetaxel in the UK NHS: REVEAL-NS
|
Talbot, T.
|
|
2017
|
103 |
S1 |
p. S40-S41
2 p.
|
artikel
|
| 157 |
46: The trials and tribulations of a biomarker driven Early Access to Medicine Scheme (EAMS)
|
Chaabouni, N.
|
|
2017
|
103 |
S1 |
p. S21-
1 p.
|
artikel
|
| 158 |
44: Time to PET-CT and final pathology report – delays in the lung cancer pathway
|
Hufton, A.
|
|
2017
|
103 |
S1 |
p. S20-
1 p.
|
artikel
|
| 159 |
145: Treating asymptomatic bone metastases in patients with lung cancer with denosumab can improve QOL
|
Leonard, P.C.
|
|
2017
|
103 |
S1 |
p. S65-S66
2 p.
|
artikel
|
| 160 |
146: Treatment of loculated malignant effusions
|
Taylor, L.
|
|
2017
|
103 |
S1 |
p. S66-
1 p.
|
artikel
|
| 161 |
72: Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer
|
Hunter, S.
|
|
2017
|
103 |
S1 |
p. S34-S35
2 p.
|
artikel
|
| 162 |
1: Tumours' Achilles' heel, that never was – Experience of re-biopsy on disease progression on EGFR-TKIs in lung cancer (NSCLC) patients from a Cancer Centre in Eastern India
|
Shrimali, R.
|
|
2017
|
103 |
S1 |
p. S1-
1 p.
|
artikel
|
| 163 |
35: Two year audit of CT-guided biopsy for lung cancer in emphysema and fibrotic interstitial lung disease patients
|
Javed, M.
|
|
2017
|
103 |
S1 |
p. S16-S17
2 p.
|
artikel
|
| 164 |
74: Tyrosine kinase inhibitors: Maintaining dose intensity with prophylactic antibiotic
|
Barrie, C.S.
|
|
2017
|
103 |
S1 |
p. S35-
1 p.
|
artikel
|
| 165 |
73: Tyrosine kinase inhibitors (TKIs) as first-line treatment for advanced EGFR mutated non-small cell lung cancer (NSCLC): a single-centre experience
|
Buckley, H.
|
|
2017
|
103 |
S1 |
p. S35-
1 p.
|
artikel
|
| 166 |
154: Uniportal VATS lobectomy and lymph node sampling; Does the lack of ports affect the number of nodes sampled?
|
Shin, J.S.
|
|
2017
|
103 |
S1 |
p. S69-S71
3 p.
|
artikel
|
| 167 |
152: Using the ambulatory care unit for admission avoidance and enhancing care for patients with lung cancer
|
Holland, L.
|
|
2017
|
103 |
S1 |
p. S69-
1 p.
|
artikel
|
| 168 |
17: Vetting fast track lung cancer referrals, a District General Hospital Experience: Is there any benefit?
|
Aslam, R.
|
|
2017
|
103 |
S1 |
p. S8-
1 p.
|
artikel
|
| 169 |
149: Virtual animation and 3-dimensional airway reconstruction using Lungpoint® to guide tracheobronchial stenting
|
Thakrar, R.M.
|
|
2017
|
103 |
S1 |
p. S67-S68
2 p.
|
artikel
|
| 170 |
51: What are the roles of risk algorithms and chest radiographs in the drive for effective referral for early lung cancer diagnosis?
|
Kedgley, E.N.
|
|
2017
|
103 |
S1 |
p. S23-
1 p.
|
artikel
|
| 171 |
5: What is the relationship between F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) characteristics and outcomes in continuous hyperfractionated accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC)?
|
Rulach, R.
|
|
2017
|
103 |
S1 |
p. S3-
1 p.
|
artikel
|
| 172 |
159: Why are patients with lung cancer not having surgery? An investigation into variable resection rates within a multi-site NHS Trust
|
Ogunsanya, M.
|
|
2017
|
103 |
S1 |
p. S73-
1 p.
|
artikel
|
| 173 |
2: XRCC6BP1: A key player in cisplatin resistance and lung cancer stem cells
|
Barr, M.P.
|
|
2017
|
103 |
S1 |
p. S1-S2
2 p.
|
artikel
|
Tijdschrift beschrijving